PCRX Q4 2017 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q4 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$79M+8.5% YoY

Gross Profit

$58M73.1% margin

Operating Income

$8M10.7% margin

Net Income

$5M5.8% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

+17.4%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$12M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$628M

Total Liabilities

$349M

Stockholders' Equity

$279M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$79M	$73M	+8.5%
Gross Profit	$58M	$49M	+17.3%
Operating Income	$8M	-$2M	+443.9%
Net Income	$5M	-$4M	+215.7%